CANCER Research Malaysia (CRMY) announced the retirement of Professor Datin Paduka Dr Teo Soo Hwang, the founding Chief Executive Officer and Chief Scientific Officer (CSO), effective April 30, 2024.
Serving as the Founding Chief Executive from January 2001 to March 2003 and again from July 2006 to February 2020, she has been a driving force behind numerous groundbreaking initiatives.
CRMY has emerged as a leading force in cancer research, making significant breakthroughs in genetic studies and personalised risk assessment tools. Under her leadership, CRMY initiated the Malaysian Breast Cancer Genetic Study, leading to significant advancements in understanding cancer risk factors and the development of the Asian Genetic Risk Calculator (ARiCa).
